Affimed GmbH
Technologiepark
Im Neuenheimer Feld 582
Heidelberg
69120
Germany
Tel: 49-6221-65307-0
Fax: 49-6221-65307-77
Website: http://www.affimed.com/
Email: info@affimed.com
169 articles about Affimed GmbH
-
Affimed Provides Update on ASCO AFM13-104 Oral Presentation
5/6/2022
Affimed N.V. announced that the American Society of Clinical Oncology has informed the Company’s collaborator that it has removed the previously announced oral presentation on AFM13-104, the investigator sponsored trial that evaluates AFM13 pre-complexed with NK cells in patients with relapsed/refractory CD30-positive lymphomas, from the upcoming conference program.
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
-
Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares
4/13/2022
Affimed N.V. announced the pricing of its previously announced public offering of 22,500,000 of its common shares at a public offering price of $4.00 per common share.
-
Cytovia could become the first company to use a combination of natural killer (NK) cells derived from induced pluripotent stem cell (iPSC) and NK engager antibodies to treat solid tumors.
-
Affimed Announces Proposed Public Offering of Common Shares - Apr 12, 2022
4/12/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it has commenced an underwritten public offering of common shares.
-
The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans. Here’s a look at some of the preclinical and early-stage studies recently presented.
-
Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting
4/10/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, provided a data update from the ongoing study of the Company’s lead innate cell engager AFM13 precomplexed with cord blood-derived natural killer cells.
-
Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress
3/31/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results for the year ended December 31, 2021, and provided an update on clinical and corporate progress.
-
Affimed to Report Full Year 2021 Financial Results & Corporate Update on March 31, 2022
3/24/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will release full year 2021 results and corporate update on Thursday, March 31, 2022.
-
Affimed Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK Cells Precomplexed with Innate Cell Engagers after Freezing & Thawing
2/9/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced the publication of pre-clinical data demonstrating the cytotoxic potency and efficacy of NK cells precomplexed with ICE® molecules after one cycle of cryopreservation.
-
Affimed to Present at Upcoming Investor Events - Feb 08, 2022
2/8/2022
Affimed N.V. announced that management will present and host one-on-one meetings at the following investor conferences during the month of February 2022.
-
Clinical Catch-Up: January 3-7
1/10/2022
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look. -
Affimed to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/5/2022
Affimed N.V. announced that its Chief Executive Officer Dr. Adi Hoess will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. Eastern Standard Time / 16:30 Central European Time.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
Clinical Catch-Up: November 22-26
11/29/2021
Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look. -
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress
11/10/2021
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results for the quarter ended September 30, 2021, and provided an update on clinical and corporate progress.
-
Affimed to Present at Upcoming Investor Conferences - Nov 09, 2021
11/9/2021
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that management will present and host one-on-one meetings at the following investor conferences during the month of November 2021.
-
Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Autologous NK Cell Product SNK01
11/8/2021
Affimed N.V. and NKGen Biotech, both clinical stage biotech companies focused on harnessing the power of the body’s innate immune system, announced the initiation of patient recruitment in the open-label, multi-center phase 1/2a study evaluating the safety, tolerability, and anti-tumor activity of the innate cell engager AFM24 - and CD16A-binding ICE®) in combination with SNK01.
-
Affimed Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition and Company-sponsored Event on AFM13
11/4/2021
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will present two posters on its innate cell engagers at the 63rd American Society of Hematology Annual Meeting and Exposition.